Back to Results

Telesis Bio Inc (TBIO)

Telesis Bio Inc. is a healthcare company focused on synthetic biology tools and services. The company manufactures and sells instruments, reagents, and related products used mainly by pharmaceutical and academic laboratories around the world. Its product suite includes the BioXp 3250 and BioXp 9600 systems, the BioXp portal for sequence design and workflow support, and a range of kits and benchtop reagents for applications such as DNA assembly, mRNA generation, next-generation sequencing library preparation, and related synthetic biology workflows. Telesis Bio also provides custom DNA synthesis solutions intended for the development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. In addition, the company has a license agreement with Regeneron Pharmaceuticals. Founded in 2011 and headquartered in San Diego, California, it was formerly known as Codex DNA, Inc. before adopting its current name in November 2022.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Market Cap Total Debt / Total Capital
OTC-TBIO
Not available
Not available
Not available
Weak
0.0%
1.801 K
0.0%
Valuation • Fair Value

Telesis Bio Inc (OTC-TBIO) Fair Value by Valuation Model

No usable valuation estimate is currently available for Telesis Bio Inc (OTC-TBIO); fair value and analyst target coverage statuses are shown explicitly below.

Primary Valuation Read

Fair Value

Not available

Data is currently unavailable.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

No usable valuation estimate is currently available for Telesis Bio Inc (OTC-TBIO). Fair value and the analyst target remain visible as coverage-status fields and should not be read as valuation signals while unavailable.

Profitability • Growth

Profitability & Growth for Telesis Bio Inc (OTC-TBIO)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

149 M

Forward revenue estimate.

EBITDA

0 K

Current operating profitability reference.

How to read profitability and growth

This section helps investors review Telesis Bio Inc (OTC-TBIO) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Telesis Bio Inc (OTC-TBIO)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

0

Weak quality score that deserves closer review.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Telesis Bio Inc (OTC-TBIO). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Dividend Profile for Telesis Bio Inc (OTC-TBIO)

Review the dividend metrics currently supported by the latest data.

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

The latest data indicates no current dividend yield for Telesis Bio Inc (OTC-TBIO). No upcoming dividend amount or event date is currently available.

Stock Forecast • Technical Outlook

Telesis Bio Inc (OTC-TBIO) Stock Forecast & Technical Outlook

Review Telesis Bio Inc (OTC-TBIO) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Sell

The 15-minute technical read for Telesis Bio Inc (OTC-TBIO) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Sell

The 1-hour technical read for Telesis Bio Inc (OTC-TBIO) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Sell

The daily technical read for Telesis Bio Inc (OTC-TBIO) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Telesis Bio Inc (OTC-TBIO) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Telesis Bio Inc (OTC-TBIO) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Telesis Bio Inc (OTC-TBIO)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Telesis Bio Inc (OTC-TBIO) has a Strong Buy consensus, with 1 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 1
Hold 0
Sell 0
FAQ • Fast Investor Answers

Telesis Bio Inc (OTC-TBIO) Stock FAQ

Data-supported answers about Telesis Bio Inc (OTC-TBIO), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
Not available
No reliable estimate from the currently supported inputs
Financial Health
Weak
Current financial-health read

A reliable fair value estimate is not currently available for Telesis Bio Inc (OTC-TBIO). This generally means the latest dataset does not contain enough valid inputs for the valuation models supported by PriceToWorth. The site does not substitute zero or publish an unsupported estimate; availability may change when updated financial data or applicable model inputs become available.

The current financial health read for Telesis Bio Inc (OTC-TBIO) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The latest available data indicates no current dividend yield for Telesis Bio Inc (OTC-TBIO).

The current market capitalization listed for Telesis Bio Inc is 1.801 K.

The ticker symbol for Telesis Bio Inc is OTC-TBIO, and the stock is listed on OTC Markets.

Telesis Bio Inc (OTC-TBIO) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Telesis Bio Inc is 0.0%, which helps investors evaluate the company’s financing structure and leverage profile.

Similar Life Sciences Tools & Services Stocks View more on OTC Markets

Comparable companies from the same industry, limited to one security per issuer.

TMO NYSE Thermo Fisher Scientific Inc Fair Value Fair Market Cap 240.9 B
DHR NYSE Danaher Corporation Fair Value Fair Market Cap 148.9 B
A NYSE Agilent Technologies Inc Fair Value Fair Market Cap 44.113 B
IQV NYSE IQVIA Holdings Inc Fair Value Fair Market Cap 43.853 B
WAT NYSE Waters Corporation Fair Value Overvalued Market Cap 41.424 B
ILMN NASDAQ Illumina Inc Fair Value Overvalued Market Cap 36.183 B
MTD NYSE Mettler-Toledo International Inc Fair Value Fair Market Cap 27.897 B
WST NYSE West Pharmaceutical Services Inc Fair Value Fair Market Cap 25.498 B
MEDP NASDAQ Medpace Holdings Inc Fair Value Fair Market Cap 17.091 B
RVTY NYSE Revvity Inc Fair Value Fair Market Cap 16.007 B
TEM NASDAQ Tempus AI Inc Fair Value Overvalued Market Cap 14.045 B
CRL NYSE Charles River Laboratories Fair Value Fair Market Cap 13.274 B
ICLR NASDAQ ICON PLC Fair Value Fair Market Cap 12.662 B
TECH NASDAQ Bio-Techne Corp Fair Value Fair Market Cap 11.349 B
AVTR NYSE Avantor Inc Fair Value Fair Market Cap 10.497 B
BIOB NYSE Bio-Rad Laboratories B Fair Value Fair Market Cap 10.007 B
BIO NYSE Bio-Rad Laboratories Inc Fair Value Fair Market Cap 10.007 B
RGEN NASDAQ Repligen Corporation Fair Value Overvalued Market Cap 9.983 B
TXG NASDAQ 10X Genomics Inc Fair Value Overvalued Market Cap 9.979 B
BRKR NASDAQ Bruker Corporation Fair Value Fair Market Cap 9.353 B